Cullinan Therapeutics (CGEM) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Rigel Pharmaceuticals (RIGL) over the past year, gaining 165.4% versus a gain of 62.7%. Over five years, RIGL leads with a +42.0% price change compared with -37.5% for CGEM. Cullinan Therapeutics is the larger company by market cap ($960.6 million vs $896.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | RIGL |
|---|---|---|
| Share price | $15.63 | $47.99 |
| Market cap | $960.59M | $896.45M |
| 1-day change | -3.82% | +4.08% |
| YTD return | +51.01% | +12.05% |
| 1-year return | +165.37% | +62.68% |
| 5-year return | -37.48% | +41.98% |
| P/E ratio (TTM) | — | 2.84 |
| Forward P/E | — | 9.72 |
| EPS (TTM) | $-3.11 | $16.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $52.24 |
| 52-week low | $5.85 | $24.95 |
| Distance from 52-week high | -32.60% | -8.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +114.01% | +31.28% |
| Average volume | 868.12K | 291.58K |
| Shares outstanding | 61.46M | 18.68M |
| Employees | 109 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed RIGL by 102.7 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
CGEM vs RIGL FAQ
Which is bigger, Cullinan Therapeutics or Rigel Pharmaceuticals?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $960.59M compared with $896.45M for Rigel Pharmaceuticals (RIGL).
Which stock has performed better over the past year, CGEM or RIGL?
CGEM returned +165.37% over the past 12 months, compared with +62.68% for RIGL (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Rigel Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cullinan Therapeutics and Biotechnology: Pharmaceutical Preparations for Rigel Pharmaceuticals.